BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32632269)

  • 1. An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathway.
    Chen J; Zhao L; Peng H; Dai S; Quan Y; Wang M; Wang J; Bi Z; Zheng Y; Zhou S; Liu Y; Chen C; Na F
    Cancer Gene Ther; 2021 Feb; 28(1-2):112-125. PubMed ID: 32632269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
    Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
    Svoboda LK; Teh SSK; Sud S; Kerk S; Zebolsky A; Treichel S; Thomas D; Halbrook CJ; Lee HJ; Kremer D; Zhang L; Klossowski S; Bankhead AR; Magnuson B; Ljungman M; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
    J Pathol; 2018 Jul; 245(3):324-336. PubMed ID: 29672864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening.
    Boretto M; Maenhoudt N; Luo X; Hennes A; Boeckx B; Bui B; Heremans R; Perneel L; Kobayashi H; Van Zundert I; Brems H; Cox B; Ferrante M; Uji-I H; Koh KP; D'Hooghe T; Vanhie A; Vergote I; Meuleman C; Tomassetti C; Lambrechts D; Vriens J; Timmerman D; Vankelecom H
    Nat Cell Biol; 2019 Aug; 21(8):1041-1051. PubMed ID: 31371824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
    Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
    Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of the menin-MLL interaction triggers menin protein degradation via ubiquitin-proteasome pathway.
    Wu Y; Doepner M; Hojnacki T; Feng Z; Katona BW; He X; Ma J; Cao Y; Busino L; Zhou F; Hua X
    Am J Cancer Res; 2019; 9(8):1682-1694. PubMed ID: 31497350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
    Borkin D; He S; Miao H; Kempinska K; Pollock J; Chase J; Purohit T; Malik B; Zhao T; Wang J; Wen B; Zong H; Jones M; Danet-Desnoyers G; Guzman ML; Talpaz M; Bixby DL; Sun D; Hess JL; Muntean AG; Maillard I; Cierpicki T; Grembecka J
    Cancer Cell; 2015 Apr; 27(4):589-602. PubMed ID: 25817203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of
    Kempinska K; Malik B; Borkin D; Klossowski S; Shukla S; Miao H; Wang J; Cierpicki T; Grembecka J
    Mol Cancer Ther; 2018 Jan; 17(1):26-38. PubMed ID: 29142068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Menin expression is regulated by transforming growth factor beta signaling in leukemia cells.
    Zhang H; Liu ZG; Hua XX
    Chin Med J (Engl); 2011 May; 124(10):1556-62. PubMed ID: 21740816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis.
    Tan P; Wang M; Zhong A; Wang Y; Du J; Wang J; Qi L; Bi Z; Zhang P; Lin T; Zhang J; Yang L; Chen J; Han P; Gong Q; Liu Y; Chen C; Wei Q
    Oncogene; 2021 Oct; 40(42):6081-6092. PubMed ID: 34471236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.
    Grembecka J; He S; Shi A; Purohit T; Muntean AG; Sorenson RJ; Showalter HD; Murai MJ; Belcher AM; Hartley T; Hess JL; Cierpicki T
    Nat Chem Biol; 2012 Jan; 8(3):277-84. PubMed ID: 22286128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target.
    Brzezinka K; Nevedomskaya E; Lesche R; Haegebarth A; Ter Laak A; Fernández-Montalván AE; Eberspaecher U; Werbeck ND; Moenning U; Siegel S; Haendler B; Eheim AL; Stresemann C
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31947537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and opportunities in targeting the menin-MLL interaction.
    Cierpicki T; Grembecka J
    Future Med Chem; 2014 Mar; 6(4):447-62. PubMed ID: 24635524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.
    Krivtsov AV; Evans K; Gadrey JY; Eschle BK; Hatton C; Uckelmann HJ; Ross KN; Perner F; Olsen SN; Pritchard T; McDermott L; Jones CD; Jing D; Braytee A; Chacon D; Earley E; McKeever BM; Claremon D; Gifford AJ; Lee HJ; Teicher BA; Pimanda JE; Beck D; Perry JA; Smith MA; McGeehan GM; Lock RB; Armstrong SA
    Cancer Cell; 2019 Dec; 36(6):660-673.e11. PubMed ID: 31821784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein.
    Murai MJ; Chruszcz M; Reddy G; Grembecka J; Cierpicki T
    J Biol Chem; 2011 Sep; 286(36):31742-8. PubMed ID: 21757704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression.
    Yokoyama A; Wang Z; Wysocka J; Sanyal M; Aufiero DJ; Kitabayashi I; Herr W; Cleary ML
    Mol Cell Biol; 2004 Jul; 24(13):5639-49. PubMed ID: 15199122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of endometrial cancer organoids establishment by cancer-associated fibroblasts.
    Wu YL; Li JQ; Sulaiman Z; Liu Q; Wang CY; Liu SP; Gao ZL; Cheng ZP
    Neoplasma; 2022 Jul; 69(4):877-885. PubMed ID: 35603951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
    Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
    Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
    Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
    Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.